Some people retired from the rapids and some were investigated for violations of discipline.

 Inviting speculation-Department of Chinese Medicine

During this period, Sinopharm, Sinopharm, and Sinopharm have successively left high-level positions, including many veterans who have worked for many years
.

Sinopharm: Li Zhiming

On January 12, Sinopharm announced on the Hong Kong Stock Exchange that Chairman Li Zhiming had proposed to the board of directors to resign as chairman and executive director of Sinopharm due to personal reasons
.

It is understood that Li Zhiming served as chairman, president, and party secretary from March 2017 to November 2017, chairman and party secretary of Sinopharm Holdings from November 2017 to November 2018, and served as Chairman and Deputy Secretary of the Party Committee
.
At the same time, he also served as director and general manager of Sinopharm Industry Investment Co.
, Ltd.
, director of Sinopharm Accord Pharmaceutical Co.
, Ltd.
, director of Sinopharm Group Pharmaceutical Co.
, Ltd.
, vice chairman of Shanghai Modern Pharmaceutical Co.
, Ltd.
and senior management positions in several subsidiaries
.

It is estimated from this that Li Zhiming resigned after serving as chairman of Sinopharm Holdings for nearly 4 years
.

In addition, on January 13, Hyundai Pharmaceutical announced that Li Zhiming had resigned from the company's seventh board of directors, vice chairman and member of the strategy and investment committee
.

Sinopharm: Li Hui

On January 12, Sinopharm announced that Li Hui, the company's director and general manager, would no longer serve as a member of the seventh board of directors, a member of the strategy committee, a member of the audit committee and the general manager of the company due to personal reasons
.

Li Hui, 52, is a veritable veteran of the Chinese Medicine Department
.
Statistics show that since 1990, Li has worked in procurement and supply station Sinopharm Tianjin, Medicines (Group) Company in Tianjin, Sinopharm Medicine Holding Co.
, Ltd.
of Tianjin positions at all levels
.
He has served as party secretary and general manager of Sinopharm since July 2018, and director of Sinopharm since August 2018
.

Li Zhiming and Li Hui of the National Pharmaceutical Department resigned on the same day, which attracted a lot of attention
.
At that time, Sinopharm's new crown vaccine was being vaccinated on a large scale and the business was advancing steadily.
However, two executives left one after another.
The outside world speculated whether it was related to the vaccine business
.
However, the company said that personal resignation has nothing to do with the vaccine
.

 National Medicines Consistent: Li Dongjiu

On March 2, Sinopharm unanimously issued an announcement stating that director Li Dongjiu applied to resign as a director of the eighth board of directors due to adjustments in work arrangements
.
The so-called "work arrangement adjustment" is a personnel appointment announced by Fosun Pharma on March 1st: the appointment of Li Dongjiu as senior vice president
.

According to information, Li Dongjiu served as Vice President and Senior Vice President of Fosun from June 2010 to January 2018, and then served as Vice President and General Counsel of Sinopharm Holdings from January 2018 to March 2021.
April 2018 He became the director of Sinopharm Accord
.

Repeated coaching changes-Chinese Medicine

On February 2, China Pharmaceuticals announced that due to work adjustments, Gao Yuwen had applied for the resignation of the company's chairman (legal representative), directors and relevant positions of the special committees of the board of directors
.

According to statistics, this is the fourth chairman of China Pharmaceuticals to resign in the past five years
.

On January 8, 2016, Zhang Benzhi applied for the resignation of the chairman (legal representative), directors and special committees of the board of directors of China Pharmaceuticals due to physical reasons.
Gao Yuwen, then the company’s managing director, was elected before the election of the new chairman.
Acting on behalf of the company's chairman of the board
.
On August 8, 2016, Tan Xinghui formally took office as the chairman of the board, and applied for resignation on September 11, 2017 due to job adjustments
.
His tenure was just over one year .
On October 9th of the same year, Jiang Xin succeeded Tan Xinghui as the new chairman, but on March 14, 2018, Jiang Xin resigned as chairman due to job adjustments and served only half a year
.
Since then, Gao Yuwen took over
.

In addition, news from multinational pharmaceutical companies continues:

On March 2, Roche Pharmaceuticals announced that Xu Xiaofeng, general manager of Roche Pharmaceuticals China General Medicine Division and Specialty Medicine Division, will leave the company on March 31 to seek external development opportunities due to personal reasons
.
After his departure from Roche Pharmaceuticals, the Specialty Drugs Division was temporarily managed by Qian Wei, Vice President of Roche Oncology First Division
.
It is reported that Xiaofeng Xu joined Roche Pharmaceuticals in February 2017 and served as Vice President of Strategy Optimization and Operations.
Later, he served as Vice President of General Medicines Division and Specialty Medicines Division and participated in the formulation of many core strategies of Roche Pharmaceuticals China
.

On March 17, Eli Lilly announced that Chen Jun, vice president of its China Diabetes Products Division, will leave Eli Lilly for personal reasons to seek external career development opportunities.
The last working day is March 31, and Jiang Yifei will take over from April 1.

.

According to the medical representative, on March 29, Gilead Sciences also announced to employees that Yu Jinyi, the former senior director of hepatitis sales, has decided to leave Gilead to seek external opportunities.
The last working day is April 16, 2021
.
It is reported that before joining Gilead Sciences, Yu Jinyi was the head of the national sales and market access strategy for Novartis's products
.
On June 15, 2020, Yu Jinyi joined Gilead Sciences as the senior director of national sales for the hepatitis team
.

It can be seen from the above three news that the resignation is for personal reasons, seeking external development opportunities
.
Perhaps, also due to the continuous advancement of China's medical reform policy, the dividends of multinational pharmaceutical companies have ceased, and they have adjusted their strategies in China.
As a result, the flow of management personnel has accelerated
.